Insider · SEC Form 4 filer
Gene Salkind
Companies
Where they file as an insider
Upexi (UPXI) Director Latest filing Jul 3, 2026
Coeptis Therapeutics (COEP) Director Latest filing Feb 11, 2026
Mobiquity Technologies (MOBQ) Director, 10% owner Latest filing Sep 15, 2025
Track record
Did their buys beat the typical stock?
Open-market buys6
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check0
Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.
Upexi (UPXI) Bought Nov 17–20, 2025 · $674K · 250,000 shares Behind typical Dec 31, 2025 $1.68 → Jun 30, 2026 $0.78 · −53.3% (typical stock +4.7%)
Upexi (UPXI) Bought Jul 11, 2025 · $100K · 20,243 shares Not counted Not counted. We have no fund price for this stock on both Sep 30, 2025 and Mar 31, 2026.
Upexi (UPXI) Bought Apr 17, 2025 · $550K · 241,229 shares Behind typical Jun 30, 2025 $2.98 → Dec 31, 2025 $1.68 · −43.6% (typical stock +2.1%)
Coeptis Therapeutics (COEP) Bought Jan 5, 2024 · $8K · 11,600 shares Not counted Not counted. We have no fund price for this stock on both Mar 31, 2024 and Sep 30, 2024.
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.